Last reviewed 2026-05-14 · How we verify

Avatrombopag tablets

Thrombopoietin receptor agonist

Thrombopoietin receptor agonist Used for Thrombocytopenia.

At a glance

Mechanism of action

Avatrombopag works by binding to and activating the thrombopoietin receptor, stimulating platelet production.

Approved indications

• Thrombocytopenia

Common side effects

• Nausea
• Headache
• Fatigue

Key clinical trials

• Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
• Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months (PHASE3)
• Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP (PHASE3)
• The Holistic Study (PHASE3)
• Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study (PHASE4)
• Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim (PHASE4)
• Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers (PHASE3)
• Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Avatrombopag tablets CI brief — competitive landscape report
• Avatrombopag tablets updates RSS · CI watch RSS
• Eisai Inc. portfolio CI